For example, FREM2 [48], CSMD1 [52], and ARID1A [53] mutations, have been identified as potential prognostic biomarkers of colorectal cancer, gastric cancer, and hepatocellular carcinoma, respectively. This evidence concerns the gene ARID1A and gastric cancer.